Colon Cancer
Research results from L. Pare and colleagues update understanding of colon cancer
Published in Hospital Law Weekly, November 20th, 2008
"To determine whether molecular parameters could be partly responsible for resistance or sensitivity to oxaliplatin (OX)-based chemotherapy used as first-line treatment in advanced colorectal cancer (CRC). We studied the usefulness of the excision repair cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD), XRCC1 and GSTP1 polymorphisms as predictors of clinical outcome in these patients," scientists in Barcelona, Spain report.
"We treated 126 CRC patients with a first-line OX/5-fluorouracil chemotherapeutic regimen. Genetic polymorphisms were determined by real-time PCR on an ABI PRISM 7000, using DNA from peripheral blood. Clinical response (CR),...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
Source: Hospital Law Weekly (2008-11-20)
More Articles from Hospital Law Weekly
- Adverse Drug Reactions
New research on adverse drug reactions from Louisiana State University summarized - AHA Solutions, Inc.
The American Hospital Association Awards its Endorsement to Identity Force's Identity Protection, Compliance and Data Breach Solutions. - AtriCure, Inc.
AtriCure Announces Investigation by the Department of Justice - Culbert Healthcare Solutions
Norm Botsford Joins Culbert Healthcare Solutions' Strategic Services Team - Eastern Michigan University
EMU School of Nursing Injects Much Needed Help Into Nursing Shortage - Ferraro Law Firm
Ft. Lauderdale Jury Awards Couple over $3 Million in Secondhand Asbestos Exposure Case - More from this issue of Hospital Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
